Ms BĂ©atrice Falise-Mirat France

Are you seeking to develop your R&D skills, enhance your innovation potential and increase your business opportunities ? Check how Medicen Paris Region can help you.

MEDICEN
CEO 

Ms Betsy Farrell United States

NYU Langone Medical Center is one of the nation’s premier academic medical centers. Our trifold mission to serve, teach, and discover is achieved daily through an integrated academic culture devoted to excellence in patient care, education, and research.Located in the heart of Manhattan, with additional facilities throughout the New York City area, NYU Langone consists of four hospitals:

NYU Langone Medical Center
Facilities Manager, Research/Education Portfolios 

Mr Thomas Ferro United States

Global Orthopedic Network, Inc.
President 

Miss Sydney FLEURANCE United States

The VIE Program is a hassle-free HR package offered by the French government which allows your company to recruit highly skilled young professionals from Europe.  It is entirely flexible and comes with many financial advantages, which explains why the program is so successful. There are currently 8200 VIEs assigned in 1800 companies worldwide and the US is the #1 destination with more than 1000 VIEs currently assigned.

VIE Program - BusinessFrance
Project Manager 

Dr JoAnne Foody United States

From developing new therapies that treat and prevent disease to helping people in need, we're committed to improving health and well-being around the world.
Merck & Co., Inc.
Global Director for Scientific Affairs, Cardiovascular 

Mr Dennis Ford United States

Life Science Nation (LSN) was founded by Dennis Ford, CEO, in 2012 to bring a better sales and marketing awareness to the life science community. LSN’s goal is to educate scientists in the basic skills required to brand, message, and market their companies.

Before LSN, Dennis was the CEO of a company that pioneered a system for uncovering global institutional investors and gauging their appetite regarding investing in hedge funds, private equity funds, and venture capital (VC) funds. The methodology used to capture and curate this valuable data was developed in part by a research team that would cold call and canvass these investors. The team would conduct a one-on-one interview with each investor that uncovered any current investment mandates they had. This allowed them to identify exactly where the capital was and specifically who had the mandate to deploy it.

After working with fundraisers in the alternative finance space for six years, Dennis wanted to bring his expertise to the life sciences and channel this fundraising experience toward the goal of moving science forward. Dennis knew from his experience in the alternatives field that many institutional investors and family offices were starting to withdraw capital from funds due to a decade of sub-par returns, initiating a trend of direct investment. This dovetailed with an accelerating trend of philanthropic investment and a desire among many investors to eradicate diseases affecting their family, friends or other groups that they have an affinity towards.

Identifying who has capital and is a fit for your company is the conundrum of the life science arena. The life science industry is poised at the entryway of a new golden age.  The one factor holding back the life science explosion is lack of capital. Dennis’s vision led him to believe that LSN could expedite the capital-raising problem by identifying active life science investors seeking emerging biotech and medtech companies and creating in-depth profiles that detail their specific preferences.  This would allow scientist-entrepreneurs to identify investors based on fit for their stage and sector, thus greatly enhancing the results of their outbound fundraising campaigns.

Dennis sought to create a match.com-like sourcing platform for the life sciences.  He knew that he needed not only current, accurate, and actionable information on both of the constituent groups who would use the platform, but also a home for the data he had started to gather on early stage life science investors.

Life Science Nation
CEO 

Mr Dan Forman United States

Wedbush Securities
Portfolio Manager 

Denis Fortier France

Eurobio Eurobio has a European-leading expertise in research, diagnostics, and corneal conservation and transportation in cold storage and organ culture. Industry sectors BioPharma Therapeutics Area Ophthalmology
Your innovative solution

iGlide and the Cornea range bring innovative lamellar conservation and transportation solutions that make the corneal graft easier, quicker and more flexible. The cornea is trephined and pre-cut in the eye bank. Lamellar membrane is placed in the iGlide, conserved in the medium and sent to the physician.

Which problem are you solving ?

iGlide saves time during surgeries, and isn

Target market segments

1/ Eye banks 2/ Other tissue brokers 3/ Surgeons 4/ Hospitals - GPO

Key value proposition

1/ non invasive 2/ inexpensive 3/ no learning curve for surgeon 4/ Best quality for the eye banks and physicians

Eurobio
CEO 

FREDERIC FORTIN France

S14 Implants  Consisted of a highly skilled and creative team of surgeons and engineers, S14 Implants brings its expertise in spinal implants and biocompatible polymers to design and manufacture a new generation of products with superior outcomes. Industry sectors Medtech Therapeutics Area Orthopedics/Orthopedic Surgery
Your innovative solution

Our unique technology combines visco elastic shock absorbers with rigid components in one device to restore the anatomical functions. Our first product 

Which problem are you solving ?

B Dyn relieves pressure on the inter vertebral disc as well as the articular facets and by controlling motion, preserves the intervertebral disc and the articular facets from final fusion. For the patients the outcomes evaluated 2 years after the surgery are superior to the standard technic of fusion.

Target market segments

Lumbar Spine Degenerative Market

Key value proposition

Superior clinical outcomes 

S14 Implants
PRESIDENT 

Candida Fratazzi United States

Simplifying Clinical Research

Boston Biotech Clinical Research (BBCR) is a strategic clinical innovation organization (SCIO) that offers simplified, customized approaches to planning and conducting clinical research. BBCR has a strong knowledge of drug safety, strategic planning and how to maximize the potential of early phase clinical research. BBCR helps biotech, pharmaceutical and device companies to deliver capital- and time-efficient clinical development programs – and thereby helps fulfill their product development strategies.

The innovative approach offered by BBCR facilitates:

  • Strategic clinical plans that, accelerate value creation from the earliest phase of clinical trials
  • Innovative simplified clinical research, using strategies that fully utilize available resources – meeting the requirements of investors, partners and regulators
  • Evidence-based trial strategies, helping to reduce risks and maximize the chances of successful outcomes
  • Design-focused trials that facilitate patient recruitment and retention, and cost-effective clinical research
Boston Biotech Clinical Research
CEO